Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)

Inclusion Criteria:

1. Patient is older than or equal to 18 years

2. The patient is an acceptable candidate for treatment with a drug-eluting stent inaccordance with the applicable guidelines on percutaneous coronary interventions, theInstructions for Use of the Resolute Integrity stent

3. The patient or legal representative has been informed of the nature of the trial andhas consented to participate and authorized the collection and release of his/hermedical information by signing a Patient Informed Consent Form

4. Intention to implant at least one Resolute Integrity stent during percutaneouscoronary intervention (PCI)

5. Patient agrees to have all study procedures performed, and is willing to comply withall protocol-required evaluations

Exclusion Criteria:

1. Known hypersensitivity or contraindication to aspirin, heparin and bivalirudin,clopidogrel and ticlopidine, cobalt, nickel, chromium, molybdenum, polymer coatings (e.g. BioLinx) or a sensitivity to contrast media, which cannot be adequatelypre-medicated

2. History of an allergic reaction or significant sensitivity to drugs such aszotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative

3. A woman who is pregnant, planning to be pregnant or lactating

4. Currently participating in another trial

5. Situation that will prevent dual anti-platelet therapy to be maintained throughout theperi-surgical period

6. Previous enrollment in the China Resolute Integrity Study